50 related articles for article (PubMed ID: 34991107)
21. Definitive Chemoradiation for Colon Cancer: a Case Report.
Jasinski V; Hahn L; Goyal U
J Gastrointest Cancer; 2023 Dec; 54(4):1353-1355. PubMed ID: 36715960
[No Abstract] [Full Text] [Related]
22. Uptake of hepatitis C direct-acting antiviral treatment in China: a retrospective study from 2017 to 2021.
Du X; Mi J; Cheng H; Song Y; Li Y; Sun J; Chan P; Chen Z; Luo S
Infect Dis Poverty; 2023 Mar; 12(1):28. PubMed ID: 36978198
[TBL] [Abstract][Full Text] [Related]
23. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ
Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496
[TBL] [Abstract][Full Text] [Related]
24. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
25. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Antonia SJ; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Kurata T; Chiappori A; Lee KH; de Wit M; Cho BC; Bourhaba M; Quantin X; Tokito T; Mekhail T; Planchard D; Kim YC; Karapetis CS; Hiret S; Ostoros G; Kubota K; Gray JE; Paz-Ares L; de Castro Carpeño J; Faivre-Finn C; Reck M; Vansteenkiste J; Spigel DR; Wadsworth C; Melillo G; Taboada M; Dennis PA; Özgüroğlu M;
N Engl J Med; 2018 Dec; 379(24):2342-2350. PubMed ID: 30280658
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
[TBL] [Abstract][Full Text] [Related]
27. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
[TBL] [Abstract][Full Text] [Related]
28. Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC).
Liu J; Bratton E; Yu X; Ladbury C; Wagner J; West H; Massarelli E; Salgia R; Pathak R; Villaflor V; Villalona-Calero M; Amini A
Am J Clin Oncol; 2022 Feb; 45(2):49-54. PubMed ID: 34991107
[TBL] [Abstract][Full Text] [Related]
29. Durvalumab for the treatment of non-small cell lung cancer.
Murakami S
Expert Rev Anticancer Ther; 2019 Dec; 19(12):1009-1016. PubMed ID: 31782989
[No Abstract] [Full Text] [Related]
30. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
[TBL] [Abstract][Full Text] [Related]
31. Locally Advanced, Unresectable Non-Small Cell Lung Cancer.
Puri S; Saltos A; Perez B; Le X; Gray JE
Curr Oncol Rep; 2020 Mar; 22(4):31. PubMed ID: 32140986
[TBL] [Abstract][Full Text] [Related]
32. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
Rajappa S; Sharma S; Prasad K
Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
[TBL] [Abstract][Full Text] [Related]
33. Durvalumab for the treatment of non-small cell lung cancer.
Mezquita L; Planchard D
Expert Rev Respir Med; 2018 Aug; 12(8):627-639. PubMed ID: 29958099
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]